MannKind Corporation

$MNKD
Biotechnology: Pharmaceutical Preparations
Health Care

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. The company offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity used for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation for the development and commercialization of a dry powder formulation of Treprostinil (Tyvaso DPI) used for the treatment of pulmonary arterial hypertension; and Thirona Bio to evaluate the therapeutic potential of TGF-ß inhibitor for the treatment of pulmonary fibrosis. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.

IPO Year: 2004

Exchange: NASDAQ

Website: mannkindcorp.com

Peers

$UTHR
$WRN

Recent Analyst Ratings for MannKind Corporation

DatePrice TargetRatingAnalyst
2/10/2025$11.00Outperform
Wedbush
12/20/2024$9.00Overweight
Wells Fargo
12/19/2024$7.00 → $10.00Sector Perform → Outperform
RBC Capital Mkts
9/9/2024$7.00 → $8.00Outperform
Leerink Partners
6/13/2024$8.00Buy
Rodman & Renshaw
10/10/2023$10.00Outperform
Wedbush
2/28/2022$6.50 → $6.00Buy
HC Wainwright & Co.
See more ratings

MannKind Corporation Press Releases

Fastest customizable press release news feed in the world

See more
  • MannKind Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

    2024 revenues of $286M, +43% v. 2023; 4Q 2024 revenues of $77M, +31% v. 4Q 20232024 net income of $28M; Non-GAAP net income of $68M 4Q 2024 net income of $7M; Non-GAAP net income of $23MReduced debt principal by $236M; remaining convertible debt of $36MYear-end 2024 cash, cash equivalents and investments of $203MAdvanced pipeline: Reported primary endpoint of INHALE-1 for Afrezza in pediatricsProgressed MNKD-101 to Global Phase 3Completed Phase 1 of MNKD-201 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today reported financial results for the quarter and year ended December 31, 2024, and provided a business update. "Th

    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • MannKind Corporation to Hold 2024 Fourth Quarter and Full Year Financial Results Conference Call on February 26, 2025

    DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), will release its 2024 fourth quarter and full year financial results after market close on Wednesday, February 26, 2025. MannKind will host a webcast beginning at 4:30 p.m. Eastern Time to discuss the financial results and provide a business update. Participating in the conference call from MannKind will be Chief Executive Officer Michael Castagna, PharmD, and Chief Financial Officer Chris Prentiss. The webcast will be accessible via a link on MannKind's website at https://investors.mannkindcorp.com/events-and-presentations. A replay will also be available in the same locatio

    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • MannKind to Present at Upcoming Investor Conferences

    DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced its participation at three investor conferences during the first quarter of 2025. MannKind's Chief Executive Officer Michael Castagna, PharmD, and Chief Financial Officer Chris Prentiss will share updates during the following investor conferences: Oppenheimer 35th Annual Healthcare Life Sciences Conference (virtual)Tuesday, February 11, 11:20 a.m. ET Leerink Partners 2025 Global Healthcare Conference

    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • MannKind Expands Executive Leadership Team

    Dominic Marasco, RPh, joins the company as President, Endocrine Business Unit, effective January 6, 2025 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focusing on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that Dominic Marasco, RPh, has joined the company as President, Endocrine Business Unit, effective January 6, 2025. Mr. Marasco is a member of MannKind's executive leadership team and reports to Michael Castagna, PharmD, Chief Executive Officer. "Dominic is an innovative leader recogniz

    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • MannKind Corporation Announces Exchange of Convertible Notes for Stock and Cash

    Company debt reduced by $194 millionCash position after closing will be in excess of $180 million DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced today that it has entered into separate, privately negotiated exchange agreements with certain holders (the "Holders") of its 2.50% Convertible Senior Notes due 2026 (the "Notes"). Under the terms of the exchange agreements, the Holders agreed to exchange an aggregate principal amount of approximately $193.7 million of Notes held by them in exchange for an aggregate of 26,749,559 shares of the Company's common stock ("Shares"). In addition, pursuant to the exchan

    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)

    Company plans to meet with FDA regarding potential sNDA submission in 1H 2025Call planned today at 8:30 a.m. (ET) to discuss company's diabetes program progression DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, today announced six-month results from its Phase 3 INHALE-1 study of Afrezza (insulin human) Inhalation Powder in children and adolescents (aged 4-17 years of age). MannKind expects to submit a request for a supplemental new drug application (sNDA) meeting with

    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India

    India has the 2nd highest burden of diabetes worldwideCDSCO decision follows existing approvals in the U.S.A. and BrazilMannKind expects to ship product for Cipla Ltd. by end of 2025 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Dec. 11, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, and Cipla Ltd. announced today that the Central Drugs Standard Control Organisation (CDSCO) in India has approved Afrezza (insulin human) Inhalation Powder in adults. The CDSCO decision follows existing approvals in the United

    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update

    Conference Call to Begin Today at 4:30 p.m. (ET) 3Q 2024 Total revenues of $70M; +37% vs. 3Q 2023YTD 2024 Total revenues of $209M; +49% vs. YTD 2023YTD 2024 Net income of $20 million; Non-GAAP net income of $45 millionOrphan lung disease studies proceeding as planned MNKD-101 Phase 3 clinical trial expands globallyMNKD-201 Phase 1 successfully completed; Plan to meet with FDA in 1H 2025 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today reported financial results for the quarter ended September 30, 2024. "Our business demonstrated double-digit revenue growth compared to last year, led by Tyvaso DPI revenues,"

    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • MannKind to Present at 2024 UBS Healthcare Conference

    DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that Chief Executive Officer Michael Castagna, PharmD, and Chief Financial Officer Chris Prentiss will share updates during a fireside chat at the 2024 UBS Healthcare Conference in Rancho Palos Verdes, Calif. The fireside chat will take place on Tuesday, November 12, at 10:15 a.m. Pacific Time. A link to the live audio webcast of the session will be available on MannKind Corporation's website at

    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases

    Met primary objective demonstrating nintedanib DPI was safe and well toleratedParticipants did not experience adverse events typically reported with oral nintedanibExpect to meet with the FDA in 1H 2025 to advance MNKD-201 into the next phase of development DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, today announced the successful completion of its first-in-human Phase 1 study of nintedanib DPI (MNKD-201) for pulmonary fibrotic diseases, including idio

    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

MannKind Corporation Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

MannKind Corporation Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

MannKind Corporation SEC Filings

See more

MannKind Corporation Leadership Updates

Live Leadership Updates

See more
  • MannKind Extends Collaboration With Thirona Bio on Fibrotic Lung Diseases

    MannKind purchased an additional convertible note issued by Thirona BioNonclinical PD study of MNKD-501 planned, with results anticipated in 2Q 2022MannKind's CEO appointed as a member of the Thirona board of directors DANBURY, Conn., Jan. 05, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced that has extended its collaboration with Thirona Bio, Inc. ("Thirona") with the purchase of a second convertible note issued by Thirona, and the appointment of Michael Castagna, PharmD as a member of the Thirona board of directors.

    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

MannKind Corporation Financials

Live finance-specific insights

See more
  • MannKind Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

    2024 revenues of $286M, +43% v. 2023; 4Q 2024 revenues of $77M, +31% v. 4Q 20232024 net income of $28M; Non-GAAP net income of $68M 4Q 2024 net income of $7M; Non-GAAP net income of $23MReduced debt principal by $236M; remaining convertible debt of $36MYear-end 2024 cash, cash equivalents and investments of $203MAdvanced pipeline: Reported primary endpoint of INHALE-1 for Afrezza in pediatricsProgressed MNKD-101 to Global Phase 3Completed Phase 1 of MNKD-201 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today reported financial results for the quarter and year ended December 31, 2024, and provided a business update. "Th

    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • MannKind Corporation to Hold 2024 Fourth Quarter and Full Year Financial Results Conference Call on February 26, 2025

    DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), will release its 2024 fourth quarter and full year financial results after market close on Wednesday, February 26, 2025. MannKind will host a webcast beginning at 4:30 p.m. Eastern Time to discuss the financial results and provide a business update. Participating in the conference call from MannKind will be Chief Executive Officer Michael Castagna, PharmD, and Chief Financial Officer Chris Prentiss. The webcast will be accessible via a link on MannKind's website at https://investors.mannkindcorp.com/events-and-presentations. A replay will also be available in the same locatio

    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)

    Company plans to meet with FDA regarding potential sNDA submission in 1H 2025Call planned today at 8:30 a.m. (ET) to discuss company's diabetes program progression DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, today announced six-month results from its Phase 3 INHALE-1 study of Afrezza (insulin human) Inhalation Powder in children and adolescents (aged 4-17 years of age). MannKind expects to submit a request for a supplemental new drug application (sNDA) meeting with

    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update

    Conference Call to Begin Today at 4:30 p.m. (ET) 3Q 2024 Total revenues of $70M; +37% vs. 3Q 2023YTD 2024 Total revenues of $209M; +49% vs. YTD 2023YTD 2024 Net income of $20 million; Non-GAAP net income of $45 millionOrphan lung disease studies proceeding as planned MNKD-101 Phase 3 clinical trial expands globallyMNKD-201 Phase 1 successfully completed; Plan to meet with FDA in 1H 2025 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today reported financial results for the quarter ended September 30, 2024. "Our business demonstrated double-digit revenue growth compared to last year, led by Tyvaso DPI revenues,"

    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • MannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024

    DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), announced today that its third quarter 2024 financial results will be released after market close on Thursday, November 7, 2024. MannKind will host a webcast beginning at 4:30 p.m. Eastern Time to discuss the quarterly results and provide a business update. Participating in the conference call from MannKind will be Chief Executive Officer Michael Castagna, PharmD, and Chief Financial Officer Chris Prentiss. The webcast will be accessible via a link on MannKind's website at https://investors.mannkindcorp.com/events-and-presentations. A replay will also be available in the same

    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • MannKind Corporation Reports 2024 Second Quarter Financial Results: Provides Clinical Development Update

    2Q 2024 Total revenues of $72M; +49% vs. 2Q 2023YTD 2024 Total revenues of $139M; +55% vs. YTD 2023YTD 2024 Net income of $9 million; Non-GAAP net income of $29 millionAdvances two orphan lung programs to human studies MNKD-101 Phase 3 clinical trial activities initiatedMNKD-201 Phase 1 clinical trial on schedule to read out 4Q 2024 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today reported financial results for the quarter ended June 30, 2024. "We achieved our ninth consecutive quarter of revenue growth and are approaching an annual revenue run rate of over $275 million based on the first half of 2024," said M

    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • MannKind Corporation to Hold 2024 Second Quarter Financial Results Conference Call on August 7, 2024

    DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), announced today that it will report its second quarter 2024 financial results before the market opens on Wednesday, August 7, 2024. A press release detailing the quarterly results will be issued the same day approximately one hour prior to the webcast. MannKind will host a webcast beginning at 9:00 a.m. Eastern Time for investors, media, and the general public. Participating in the conference call from MannKind will be Chief Executive Officer Michael Castagna, PharmD, and Chief Financial Officer Chris Prentiss. The webcast will be accessible via a link on MannKind's website a

    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • MannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development Update

    1Q 2024 Total revenues of $66M; +63% vs. 1Q 20231Q 2024 Net income of $11M; Non-GAAP net income of $15M$304M of cash and cash equivalents and investments at March 31, 2024In early April, repaid Midcap senior-secured debt and Mann Group convertible debt totaling approximately $37M FDA Fast Track designation and IND clearance received for MNKD-101 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today reported financial results for the quarter ended March 31, 2024. "We achieved our eighth consecutive quarter of revenue growth putting us on a run rate of over $250 million in revenue for 2024," said Michael Castagna, PharmD, Chi

    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024

    DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2024 first quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Wednesday, May 8, 2024. Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at https://investors.mannkindcorp.com/events-and-presentations under Events & Presentations. About MannKind CorporationMannKind Corporation (NASDAQ:MNKD) focuses on the development and commercialization of innovative therapeutic products and devices to ad

    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • MannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development Update

    2023 Total revenues of $199M; +99% vs. 20224Q 2023 Total revenues of $58M; +62% vs. 20224Q 2023 Net income of $1M; Non-GAAP net income of $7M$302M of cash and cash equivalents and investments at December 31, 2023 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today reported financial results for the quarter and full year ended December 31, 2023. "We doubled our total revenues to nearly $200 million in 2023 and ended the year with a robust fourth quarter total revenue of $58 million," said Michael Castagna, PharmD, Chief Executive Officer of MannKind Corporation. "With our strong year-end cash position of over

    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

MannKind Corporation Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more